BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
BRUKINSA® (zanubrutinib) continues to show progression free survival (PFS) benefit compared with ibrutinib in extended follow-up of patients with relapsed/refractory...




















